NCI-2023-08387

A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Nonsmall Cell Lung Cancer (HARMONi-3)

This is a large, carefully designed research study comparing two immunotherapy-based treatments for lung cancer that has spread. Researchers want to find out if using Ivonescimab with chemotherapy is better than the current standard treatment, which is Pembrolizumab with chemotherapy. Because it's a "double-blind" study, neither the patients nor the doctors know which treatment each patient is getting. This helps make the study results more accurate. The study is being done in many different places to ensure the results apply to a wide range of patients.

Immunotherapy: The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05899608

Clinical Trial Site: Sinai

To see all available clinical trials click here.